LINDA SHEPPARD-REECE: Open Payments
NPI 1023495538 · PEMBROKE, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$489 in 27 payments from 9 companies in 2025. Trend: 2023 $112 · 2024 $160 · 2025 $489
Food & beverage: $489
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $135 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Alkermes, Inc. | 4 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Lundbeck LLC | 1 | $15 |
Products named: VRAYLAR, REXULTI, ARISTADA, CAPLYTA, FANAPT, UZEDY, INGREZZA, INVEGA SUSTENNA.
Industry payments across MA — which companies pay providers there.
